Clinical Trial Search

Primary: Number of Participants With a Positive Immune Response Following Vaccination Determined by Interferon (IFN) Gamma Enzyme-linked Immunosorbent Spot (ELISpot) — 12; 10…

Primary: IDEEL (Impact of Dry Eye on Daily Life) Quality of Life - Work Subsection — 81.4; 81.4 score on a scale — p=<0.05

Primary: Number of Participants With Intubation or Death — 5; 1 Participants

Primary: Change in Motor Function During Levodopa Withdrawal. — -4.210; -5.114 score on a scale

Primary: Clinical Response — 0; 3; 7; 19 Participants

Primary: Change in Best Corrected Visual Acuity (BCVA) — 1.0; 0.8; 0.9; 2.5 Letters Correctly Read — p=0.16

Primary: Participants With a Surgical Site Infection — 14; 20 Participants — p=0.27

Primary: Proportion of Patients Achieving an Investigators Global Assessment (IGA) of 0 (Clear) or 1 (Almost Clear) and a Decrease of at Least 2 Points in IGA in Treated…

Primary: Annualized Bleeding Rate (ABR) for All Bleeding Episodes — 4.19; 1.51 bleeds/year/participants

Primary: Overall Survival — 0; 0 Proportion of participants

Primary: Complete Response — 45 Percentage of Participants

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 2; 4; 0; 0 Participants

Primary: Change in Worry-related Sleep Disturbances — -4; -1 units on a scale

Primary: Change From Baseline Comfort Score — 28.99; -0.29 Units on a scale

Primary: Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT) — 2; 1; 2; 0 Participants